TIBET PHARMA(SH:600211) Southwest Securities·2025-03-19 03:31Investment Rating - The report does not specify a clear investment rating for the company [1][6]. Core Views - The company's performance in 2024 met expectations, with a total revenue of 28.1 billion yuan, a year-on-year decrease of 10.5%, and a net profit attributable to the parent company of 10.5 billion yuan, an increase of 31.3% [6][9]. - The sales of the main product, New Huo Su, experienced a decline, with a total sales revenue of 24.3 billion yuan, down 13.6% year-on-year [6][9]. - The company plans to continue high cash dividends, proposing a cash dividend of 0.728 yuan per share, totaling 630 million yuan, which accounts for 60% of the net profit attributable to shareholders [6][9]. Summary by Sections Financial Performance - Revenue for 2024 was 28.1 billion yuan, with a growth rate of -10.45% [2][9]. - Net profit attributable to the parent company was 10.5 billion yuan, with a growth rate of 31.26% [2][9]. - Earnings per share (EPS) for 2024 was 3.26 yuan [2][9]. - The return on equity (ROE) was 26.75% [2][9]. Future Projections - Revenue projections for 2025-2027 are 29.6 billion yuan, 33.2 billion yuan, and 37.3 billion yuan, respectively, with growth rates of 5.56%, 12.14%, and 12.26% [2][9]. - Net profit projections for 2025-2027 are 9.4 billion yuan, 10.5 billion yuan, and 11.3 billion yuan, respectively [6][9]. Product Sales Forecast - New Huo Su sales are projected to be 25.1 billion yuan in 2025, with a growth rate of 3% [8][9]. - Other product sales are expected to grow significantly, with projections of 452.8 million yuan in 2025, reflecting a growth rate of 21.1% [8][9]. Cost and Profitability - The gross profit margin for 2024 was 94.2%, with a slight decrease expected in the following years [6][9]. - The company aims to control the cost ratio to within 70% for 2025 [6][9].